拉西巴库单抗在儿童中的外推与给药建议
本研究基于群体药代动力学模型,将成人拉西巴库单抗的处置外推至儿童,评估体重与成熟过程对药代参数的影响,并提出分体重段的儿童给药方案,以优化目标暴露。
要点
- 年龄相关的成熟过程可能影响极年幼患者的拉西巴库单抗清除。
- 推荐分4个体重段给药:≤1.5 kg为75 mg/kg,<10 kg为55 mg/kg,<50 kg为45 mg/kg,>50 kg为40 mg/kg。
- 该方案基于群体药代动力学外推,临床使用需结合具体患者评估。
核心结论
- 年龄相关成熟过程可能影响极年幼患者的拉西巴库单抗清除,所提方案考虑了体重与成熟过程对消除的影响。
研究设计与样本
- 采用群体药代动力学模型,将成人拉西巴库单抗处置外推至儿童,并评估不同外推场景包括分体重段给药方案。
主要发现
- 基于实际考虑,需采用含4个剂量水平的分体重段给药方案以优化儿童群体的目标暴露。
关键数值与推荐
- 推荐剂量为:≤1.5 kg者75 mg/kg,<10 kg者55 mg/kg,<50 kg者45 mg/kg,>50 kg者40 mg/kg。
- 比较了AUC、Cmax及血清拉西巴库单抗浓度≥猴最高血清保护抗原浓度且持续至少28天的时间与现行美国批准剂量。
临床怎么用
- 临床可依据儿童体重段选择相应拉西巴库单抗剂量,并关注极年幼患者因成熟过程可能存在的清除差异。
局限性
- 儿童处置未在临床试验中研究,结果基于成人数据外推的群体药代动力学模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The US Food and Drug Administration's Animal Rule allows for the approval of drugs when human efficacy studies are not ethical. While the therapeutic doses of raxibacumab, a monoclonal antibody for the prophylaxis and treatment of inhalational anthrax, have been based on pharmacokinetic data from adult subjects, its disposition in children has not been investigated in clinical trials. Here we evaluate the effect of demographic covariates and maturation processes on the pharmacokinetics of raxibacumab and explore opportunities for the optimisation of paediatric doses. METHODS: A population pharmacokinetic model was used as basis for the extrapolation of raxibacumab disposition from adults to children. Different extrapolation scenarios, including weight-banded dosing regimens, were considered to assess the effect of growth and maturation on the pharmacokinetic parameters of interest. Area under the concentration-time curve, maximum plasma concentration and the time of serum raxibacumab concentrations greater than or equimolar to the highest serum protective antigen concentrations observed for at least 28 days in any monkey challenged with Bacillus anthracis that died were derived and compared with the currently approved US doses. RESULTS: Based on practical considerations, a weight-banded dosing regimen consisting of 4 dose levels (75 mg/kg for individuals ≤1.5 kg, 55 mg/kg for individuals <10 kg, 45 mg/kg for individuals <50 kg, 40 mg/kg for all individuals >50 kg) was required to optimise target exposure across the paediatric population. CONCLUSIONS: Age-related maturation processes may affect raxibacumab clearance in very young patients. The proposed dosing regimens take into account effects of body weight and maturation processes on the elimination of raxibacumab.
引用
- Oosterholt SP, Della Pasqua O. Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years. Br J Clin Pharmacol. 2021. PMID: 33974281. doi:10.1111/bcp.14893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。